Research programme: inflammation therapy - Provid/BTG
Latest Information Update: 21 Aug 2019
At a glance
- Originator BTG; Provid Pharmaceuticals
- Class Small molecules
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 07 May 2007 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 14 Jul 2003 Preclinical trials in Inflammation in USA (unspecified route)